Prelude Therapeutics to Present at Major Healthcare Event
Prelude Therapeutics Incorporated (PRLD), a leading clinical-stage company focused on precision oncology, is set to participate in a prominent global healthcare conference. This event highlights the latest advancements in cancer treatment and research. With a focus on innovative therapies, Prelude is actively engaged in developing groundbreaking solutions for patients in urgent need.
Details of the Event
On March 11, 2025, Prelude's leadership team will engage in a fireside chat during the Barclays 27th Annual Global Healthcare Conference. Scheduled for 12:30 p.m. ET, this session will feature insights from Kris Vaddi, Ph.D., Chief Executive Officer; Jane Huang, M.D., President and Chief Medical Officer; and Bryant Lim, Chief Financial Officer. Their discussion will center around the company's advancements and future directions in precision oncology.
Webcast Availability
For individuals unable to attend the event in person, Prelude Therapeutics is providing a live webcast of the fireside chat. This can be accessed via the company’s official website under the Events and Presentations section. In addition to the live stream, a recorded version of the session will be archived for 90 days, allowing audiences to catch up on the discussions at their convenience.
Focus on Precision Medicine
Prelude Therapeutics is dedicated to revolutionizing cancer treatment through its extensive pipeline of innovative drug candidates. The company's portfolio includes several first-in-class SMARCA2 degraders and an advanced CDK9 inhibitor, all designed to meet the critical needs of cancer patients. By harnessing the power of targeted protein degradation, Prelude aims to deliver next-generation therapies that will enhance the effectiveness of cancer treatments.
Investor Relations
Prelude invites investors and interested parties to learn more about its innovative approach to oncology. For inquiries, Robert Doody, the Senior Vice President of Investor Relations, is available at 484.639.7235 or via email.
About Prelude Therapeutics
Prelude Therapeutics is at the forefront of developing targeted oncology therapies that address significant unmet medical needs. The company is committed to extending the benefits of precision medicine to all cancer patients through innovative solutions and strategic partnerships.
Frequently Asked Questions
What is the Barclays Healthcare Conference?
The Barclays Healthcare Conference is an annual event that brings together leaders in healthcare and biotechnology to discuss current innovations, trends, and challenges in the industry.
Who will represent Prelude Therapeutics at the conference?
Kris Vaddi, Ph.D., Jane Huang, M.D., and Bryant Lim are the key executives who will represent Prelude Therapeutics in the fireside chat at the conference.
How can I access the webcast of the fireside chat?
The webcast can be accessed through Prelude Therapeutics' official website in the Events and Presentations section on the day of the event.
What kind of therapies is Prelude Therapeutics developing?
Prelude is developing several innovative therapies, including SMARCA2 degraders and a CDK9 inhibitor, aimed at improving treatment outcomes for cancer patients.
How can investors contact Prelude Therapeutics?
Investors can contact Robert Doody, Senior Vice President of Investor Relations, at 484.639.7235 for any inquiries related to the company.